Antipsychotics in the elderly: Typical or atypical?;Antipsicóticos en ancianos, ¿típicos o atípicos?

Medicina Clinica

Volumn 126, Issue 11, 2006, Pages 415-417

  Pujol Doménech, Joaquin ^a   De Azpiazu Artigas, Pilar ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b Benito Menni Complex Assistencial en Salut Mental   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

DEPRESSION; DRUG TOLERANCE; EDITORIAL; GERIATRIC PATIENT; HUMAN; PSYCHOSIS; SYMPTOM;

EID: 33646352968     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086130     Document Type: Editorial

References (18)

1. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA. 2005; 293:596-608.
2. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000;22: 1068-84.
3. Lonegan E, Luxenberg J, Colford J. Haloperidol para la agitacion en la demencia. En: Cochrane Library plus en español. Update Software; 2002.
4. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PLJ, Eriksson S. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-55.
5. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clamette R, et al. A randomized placebo- controlled trial of risperidone for the treatment of aggression, agitation and psychosis of dementia. J Clin Psychiatry. 2003:64;134-43.
6. De Deyn PP, Jeste D, Mintzer J. Aripiprazole in dementia of the Alzheimer's type. Actas del 16th Annual Meeting of the American Association for Geriatric Psychiatry; 2003, marzo 14; Honolulu.
7. Gill Sudeep S, Rochon PA, Hermann N, Lee PE, Sykora K, Gunraj N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330;445.
8. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161:1113-5.
9. Luna B, Feinglos NM. Drug induced hiperglicemia. JAMA. 2001;286: 1945-8.
10. Nasrallah H. A review of the effect of atypical antipsychotics on weigth. Psychoneuroendocrinolpgy. 2003;28 Suppl 1:83-96.
11. Pujol J, De Azpiazu P. Us de neurolèptics en la demència. Butlletí de Informació Farmacoterapèutica del Consorci Sanitari de Barcelona. 2003; 44:1-6.
12. Pujol J, De Azpiazu P. Neurolépticos atipicos en ancianos. En: Ribera JM, editor. Esquizofrenia en las personas mayores. Monografías en geriatría. Barcelona: Editorial Glosa; 2004.
13. NOVARTIS Farmacéutica. Interrupción del suministro de la especialidad Meleril [carta circular]. Enero de 2005.
14. Pérez J, Marín N, Vallano A, Castells X, Capella D. Consume y gasto de fármacos antipsicóticos Actas Esp Psiquiatr. 2005;33:110-6.
15. Liperoti R, Gambassi G, Lapane KI, Chiang C, Pedone C, Mor V, et al. Conventionaln and atypical antipsychotics and the risk of hospitalization for ventricular arrythmias or cardiac arrest. Arch Intern Med. 2005;165: 696-701.
16. Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S. National Institute of Mental Health clinical antipsycnotic trials of intervention effectiveness (CATIE): Alzheimer's disease trial methodology. Am J Geriatric Psychiatry. 2001;9:346-60.
17. Medrano J. Visado para antipsicóticos atipicos. Norte de Salud Mental. 2005;22:60-5.
18. Consenso Español Demencias. Madrid: Saned Editores; 2005.